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care hospital in India. Rheumatic heart disease and primary
cardiomyopathies are also present in significant proportion. In
ADHF patients there is low use of evidence-based therapies
(ACE inhibitors/ARBs, beta-blockers) and short-term mortality is
high.
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Evaluation and assessment of rosuvastatin 40 mg
treatment in high risk dyslipidemic patients
(EARTH Study)
R. Karnik, A. Trailokya, P. Kamlesh, Q. Mukaddam, M. Naik
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Background: Rosuvastatin is commonly used in the treatment of
dyslipidemia, however, studies with rosuvastatin 40 mg in Indian
patients with high cardiovascular risk are lacking.
Objective: To assess the safety and efficacy of rosuvastatin 40mg
in dyslipidemic patients with high cardiovascular risk.
Methods: In an open label, non-comparative, multicentric, post
marketing observational study, 574 Indian patients were
enrolled. Treatment was started with rosuvastatin 40 mg once
daily for one month. After one month, patients achieving target
goal of LDL-C < 70 mg/dl were shifted to rosuvastatin 20 mg once
daily for next two months and those not achieving were
continued on 40mg. At third month, patients achieving LDL-C <
70 mg/dl continued 20 mg and those not achieving the target goal
were continued on 40mg for next three months. Lipid profile was
repeated after six month. The primary evaluation parameter was
percentage of patients achieving target serum LDL-C goal < 70
mg/dl at the end of one, three and six month. The secondary
evaluation parameters included percentage reduction in serum
LDL-C, serum. total cholesterol, serum triglyceride and percent-
age increase in S. HDL-C level at the end of one, three and six
month, and effect on serum creatinine at six months. Global
assessment for efficacy and tolerability was recorded by the
doctor and patient at the end of six months. All adverse events
were also recorded.
Results: Compared to baseline, there was significant increase in
number of patients achieving serum LDL <70 mg/dl at one, three
and six months. Similarly, significant reduction in serum LDL,
total cholesterol and triglyceride level and increase in HDL was
seen at one, three and six months. There was no significant
effect on serum creatinine level. Most of the patients reported
efficacy as either excellent or good as evaluated by both doctors
and patients. Close to 95% of the patients reported tolerability as
“good” as per global evaluation of tolerability by patients as well
as doctors. Rosuvastatin was generally well tolerated. The
incidence of adverse event was 9.9% with headache, myalgia,
constipation and vomiting being the commonly reported
adverse events. All the adverse events were of mild to moderate
intensity and all of them resolved during the treatment. None of
the patient required termination of treatment because of
adverse event.
Conclusion: Rosuvastatin is effective and well tolerated medicine
for the treatment of dyslipidemic patients with high cardiovas-
cular risk.
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Background: This study was conducted to evaluate the effect of
telmisartan or telmisartan with hydrochlorothiazide (HCTZ) with
or without patient’s education about the blood pressure (BP). This
education was focused on the reduction of body weight and
healthy life-style.
Methods: 922 patients of essential hypertension were included in
this study. The inclusion criteria were: essential hypertension
(BP140/90mmHg or BP130/80mmHg in diabetic patients), age >
18 year and treatment of hypertension with at least one of the
above anti-hypertensive drug. A total of 387 patients were treated
with telmisartan and 535 patients with telmisartan with HCTZ.
The randomization ratio for life style programme was 2:1. The life
style programme included a 30 mins structured interview and
written detailed materials focused on the healthy life style, diet
and weight reduction. Patients were followed up at 4 to 8 weeks
intervals.
Results: The decrease of BP (both systolic & diastolic) during tel-
misartan/telmisartan with HCTZ treatment was statistically
highly significant (P<0.001). The decrease of BP below 140/90
mmHg was attained in 78.55% patients treated with telmisartan
and in 66.64% patients treated with telmisartan with HCTZ. The
final BP values (both systolic and diastolic) of patients enrolled in
the life style programmewere not significant different from the BP
value in patients without the life style programme. The life-style
programme had more “normotensive” patients (73.41%) than the
patients not enrolled in the life style programme (69.70%). The
difference was not significant. The mean decrease of body weight
in the life-style programme patients was 2.64±4.11 kg, which was
significantly more than in the non-life style programme patients
(0.65±3.85 kg, p<0.05).
Conclusions: The telmisartan either alone or in combination with
hydrochlorothiazide is an effective and safe anti-hypertensive
drug. The educational programme led to the decrease of body
weight, but did not significantly change the BP values.
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amlodipine e Induced edema in hypertensives
patients
D.P. Singh, K. Sinha, A.K. Shrivastava, S.S. Singh
S S Hospital, IMS, Banaras Hindu University, Varanasi, India
Background: Ankle oedema is a common adverse effect of
Amlodipine, a widely used L-type Calcium Channel Blocker (CCB),
seen in about 15% of patients receiving the drug. Cilnidipine is a
newer third generation L/N-type CCB and is approved for the
treatment of essential hypertension. This study was, therefore,
planned to determine whether Cilnidipine therapy can produce
resolution of Amlodipine-induced oedema while maintaining
adequate control of blood pressure.
Methods: This study was carried out on 56 patients of essential
hypertension with Amlodipine-induced oedema. Concomitant
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 1es 1 4 3 S87
